Lesson plan

PSIL-002

PSIL-002 is a non-hallucinogenic serotonin 5-HT 1 receptor modulator which is under development for the treatment of depressive disorders, mood disorders, neurodegenerative disorders, and substance-related disorders. Its route of administration is unspecified. The drug's effects in animals have been described. PSIL-002 is being developed by Psilera. As of August 2022, it is in the preclinical research stage of development for all indications. The drug is an analogue of dimethyltryptamine (DMT), but its exact chemical structure does not yet seem to have been disclosed.

Back to article

Article summary

PSIL-002 is a non-hallucinogenic serotonin 5-HT 1 receptor modulator which is under development for the treatment of depressive disorders, mood disorders, neurodegenerative disorders, and substance-related disorders. Its route of administration is unspecified. The drug's effects in animals have been described. PSIL-002 is being developed by Psilera. As of August 2022, it is in the preclinical research stage of development for all indications. The drug is an analogue of dimethyltryptamine (DMT), but its exact chemical structure does not yet seem to have been disclosed.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.